Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
暂无分享,去创建一个
T. Bosse | E. M. van der Steen-Banasik | V. Smit | I. Jürgenliemk-Schulz | R. Nout | J. Mens | C. Creutzberg | J. Jobsen | L. Lutgens | E. Peters
[1] J. W. Kim,et al. 1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial , 2014 .
[2] A. Usubutun,et al. Lymphovascular space involvement is the sole independent predictor of lymph node metastasis in clinical early stage endometrial cancer , 2013, Archives of Gynecology and Obstetrics.
[3] K. Lee,et al. Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer , 2013, The Australian & New Zealand journal of obstetrics & gynaecology.
[4] H. Putter,et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. , 2012, European journal of cancer.
[5] P. Goodfellow,et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. , 2012, Gynecologic oncology.
[6] Lonneke V van de Poll-Franse,et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Putter,et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial , 2010, The Lancet.
[8] Hein Putter,et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Flannelly,et al. Lymphovascular space involvement in early stage well‐differentiated endometrial cancer is associated with increased mortality , 2009, BJOG : an international journal of obstetrics and gynaecology.
[10] A. Gadducci,et al. Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. , 2009, Anticancer research.
[11] N. Yaegashi,et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. , 2009, Gynecologic oncology.
[12] T. Whelan,et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis , 2009, The Lancet.
[13] Andrea Mariani,et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. , 2008, Gynecologic oncology.
[14] E. Anteby,et al. Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] D. Levine,et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology , 2007, International Journal of Gynecologic Cancer.
[16] G. Thomas,et al. Endometrial cancer--revisiting the importance of pelvic and para aortic lymph nodes. , 2007, Gynecologic oncology.
[17] H. Boezen,et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. , 2005, Gynecologic oncology.
[18] P. Koper,et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Maiman,et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .
[20] R. Scully,et al. Unusual Epithelial and Stromal Changes in Myoinvasive Endometrioid Adenocarcinoma: A Study of Their Frequency, Associated Diagnostic Problems, and Prognostic Significance , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[21] D. Mutch,et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer , 2002 .
[22] P. Koper,et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial , 2000, The Lancet.
[23] T. Kawarabayashi,et al. The grading of lymphovascular space invasion in endometrial carcinoma , 1999, Cancer.
[24] R. Kurman,et al. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus , 1992, Cancer.
[25] B. Bundy,et al. Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.
[26] V. Abeler,et al. Postoperative External Irradiation and Prognostic Parameters in Stage I Endometrial Carcinoma: CLINICAL AND HISTOPATHOLOGIC STUDY OF 540 PATIENTS , 1980, Obstetrics and gynecology.